期刊文献+

新活素对急性心衰患者心率变异性的影响 被引量:19

Effects of Lyophilized Recombinant Human Brain Natriuretic Peptide on Heart Rate Variability in Acute Decompensated Heart Failure
暂未订购
导出
摘要 目的观察新活素——冻干重组人脑利钠肽(Lyophilized Recombinant Human Brain Natriuretic Peptide,Lrh-BNP)治疗急性失代偿心力衰竭(Acute decompensated heart failure,ADHF)对心脏自主神经功能的影响。方法对照组49例,进行基础抗心衰治疗;Lrh-BNP组45例,在基础抗心衰治疗上静脉注射Lrh-BNP 24 h。所有患者治疗前后均进行24 h Holter检查,对Lrh-BNP治疗前后及对照组进行心率功率谱时域和频域分析。结果Lrh-BNP组治疗后心率变异性(HRV)值较对照组显著改善,其中时域指标:全部正常R-R间期的标准差(SDNN)、每5 min R-R间期均值的标准差(SDANNI)、SDNN的均值(SDNNI)、正常相邻R-R间期差值的均方根RMSSD、正常相邻R-R间期差值>50 ms的百分比(PNN50)、心率均显著改善(P<0.05);频域指标:总频谱(TF)、低频(LF)和高频(HF)亦明显改善(P<0.05)。结论Lrh-BNP可改善ADHF患者的心率变异性。 Objective To study the effect of lyophilized recombinant human brain natriuretic peptide ( Lrh-BNP ) on heart rate variability in acute decompensated heart failure (ADHF). Methods Forty nine cases with ADHF were treated by routine measure (as control). Forty five cases were treated with Lrh-BNP for 24 hours based on the routine measure. The heart rate power spectral density and time-domain were analyzed with 24 hour electrocardiographic monitoring before and after using Lrh-BNP. Results Compared with the control group,time-domain analysis in Lrh-BNP after the treatment revealed a significant improved in SDNN, SDANNI, SDNNI, RMSSD, PNN50 ( P 〈 0.05 ). Heart Rate and frequency domain analysis revealed marked improve of total,low and high frequency components (P 〈 0.05 ). Conclusions Lrh-BNP can significantly improve the heart rate variability in ADHF.
出处 《实用全科医学》 2007年第6期485-486,共2页 Applied Journal Of General Practice
关键词 冻干重组人脑利钠 心力衰竭 心率变异性 Lyophilized recombinant human brain natriuretic peptide Acute Decompensated Heart Failure Heart rate variability
  • 相关文献

参考文献5

二级参考文献29

  • 1宋有城,万立礼,胡桃红,朱俊,王莉,李晶.充血性心力衰竭患者心率变异性分析[J].中华心血管病杂志,1995,23(2):107-109. 被引量:58
  • 2陆再英.心率变异分析方法学的标准化及结果的正确评价[J].中国心脏起搏与心电生理杂志,1996,10(4):222-224. 被引量:62
  • 3Packer M. The neurohormonal hypothesis:A theory to the mechanism of disease progression in heart failure[J]. J Am Coll Cardiol, 1992,20( 1 ) : 248-254.
  • 4Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endotholine-1-mediated vasoconstriction in severe chronic heart failure [ J ]. Lancet,1995,346(8976) :732-736.
  • 5Pettetta M, Condorelli GL, Spinelli L, et al. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure[ J]. Am Heart J,2000,140[ Suppl ] : E28.
  • 6Kapadia S, Dibba Z, Kurrelmeyer K, et al. The role of cytokines in the failing human heart[J]. Cardiol Clin, 1998,16(4) :645-656.
  • 7Chen HH, Burner JC. The natriuretic peptides in heart failure:Diagnosis and therapeutic potentials[J] .Proc Assoc Am Physicians, 1999,111(5) :406-416.
  • 8Hobbs RE, Mills RM. Therapeutic potential of nesiritide ( recombinant B-type natriuretic peptide) in the treatment of heart failure[J]. Expert Opin Investig Drugs, 1999,8(6) : 1063-1072.
  • 9Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic,neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure[J] .J Card Fail, 1998,4( 1 ):37-44.
  • 10Mills RM, Lejemtel TH, Horton DP, et al. Sustained hemodenamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure. A randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group[ J ] . J Am Coll Cardial, 1999,34 ( 1 ) : 155-162.

共引文献55

同被引文献167

引证文献19

二级引证文献142

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部